# L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

> **NCT04924413** · PHASE2 · TERMINATED · sponsor: **Quanli Gao** · enrollment: 9 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT04924413
- **Lead sponsor:** Quanli Gao
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-01
- **Primary completion:** 2024-07-02
- **Final completion:** 2024-07-02
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04924413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04924413, "L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04924413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*